A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
HIV Infection, Infection, Human Immunodeficiency Virus
About this trial
This is an interventional treatment trial for HIV Infection focused on measuring HIV-1 LEXIVA Ritonavir Once-daily
Eligibility Criteria
Inclusion criteria: Subjects with HIV-1 infection. Are willing and able to understand and provide written consent prior to participation in this study. Exclusion criteria: Are pregnant or breastfeeding. Have an active AIDS condition, pancreatitis, poor kidney function, or clinically relevant hepatitis. Have certain medical conditions that may make participation unsafe. Take medication that may interact with the study medication. Have a history of allergy to any of the study drugs or any excipients therein. Other inclusion/exclusion criteria to be evaluated by the physician.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
FPV/r200
FPV/r100
Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
Fosamprenavir/ritonavir 1400/100mg QD